BioSpace News Archive

Medivir AB announced that Medivir’s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor.

Interactomics pioneer Depixus has launched its game-changing MAGNA™ technology access program with the deployment of the first MAGNA One™ beta prototype instrument in the laboratory of Professor Jean-François Allemand, Department of Physics at the École Normale Supérieure, Paris.

Resalis Therapeutics announced the closing of a €10 million Series A financing round led by Sunstone Life Science Ventures with participation from existing investors including Claris Ventures and angel investors.

First Wave BioPharma, Inc.,today announced that James Sapirstein, Chairman and CEO of First Wave BioPharma, has issued a Letter to Stockholders highlighting the Company’s recent accomplishments and plans for 2024.

Zymeworks Inc., a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, provided an update on key strategic priorities for 2024 and 2025.

Kynexis announced today that the first healthy volunteers have been dosed in its first-in-human phase 1 study of KYN-5356. KYN-5356, a clinical-stage small molecule targeting a key enzyme in the kynurenine pathway known as KAT-II, is being developed for cognitive impairment associated with schizophrenia (CIAS).

Bio-Techne Corporation (NASDAQ: TECH) today announced it will present its portfolio of products and solutions to enable cell and gene therapy development and manufacturing at Phacilitate’s Advanced Therapies Week , taking place January 16-19 at the Miami Beach Convention Center in Miami, Florida.

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, reported business highlights and preliminary U.S. ZTALMY® net product revenue for the fourth quarter and year ended December 31, 2023.

Bond Biosciences, Inc. announced today that it is presenting at Biotech Showcase™ 2024.

Mission Bio announced the appointment of Brian Kim as Chief Executive Officer.